Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGIO Agios Pharmaceuticals	$38.46 +3.2%	$36.93	$23.42 ▼ $62.58	$2.16B	0.8	973,578 shs	647,317 shs
DNLI Denali Therapeutics	$15.55 -0.1%	$14.36	$10.57 ▼ $33.33	$2.28B	1.36	1.82 million shs	2.02 million shs
OCUL Ocular Therapeutix	$12.32 +3.8%	$11.06	$5.78 ▼ $12.91	$2.07B	1.49	2.01 million shs	1.77 million shs
TYRA Tyra Biosciences	$12.64 +5.3%	$10.48	$6.42 ▼ $29.60	$639.57M	1.08	215,988 shs	192,305 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGIO Agios Pharmaceuticals	-3.97%	-0.51%	-6.85%	+23.38%	-19.39%
DNLI Denali Therapeutics	+0.52%	+5.06%	+13.90%	+17.87%	-37.14%
OCUL Ocular Therapeutix	-3.50%	-3.57%	-2.78%	+71.04%	+30.30%
TYRA Tyra Biosciences	+2.48%	+11.01%	+8.50%	+36.05%	-45.60%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AGIO Agios Pharmaceuticals	4.3417 of 5 stars	3.4	2.0	4.3	2.9	0.8	1.9
DNLI Denali Therapeutics	4.2928 of 5 stars	3.6	1.0	4.7	3.9	3.3	0.0
OCUL Ocular Therapeutix	4.0432 of 5 stars	3.5	3.0	4.1	3.7	0.8	0.0
TYRA Tyra Biosciences	2.0327 of 5 stars	3.5	1.0	0.0	1.6	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AGIO Agios Pharmaceuticals	2.75	Moderate Buy	$56.33	46.47% Upside
DNLI Denali Therapeutics	3.12	Buy	$33.62	116.18% Upside
OCUL Ocular Therapeutix	3.00	Buy	$17.20	39.61% Upside
TYRA Tyra Biosciences	3.00	Buy	$30.83	143.93% Upside

Current Analyst Ratings Breakdown

Latest TYRA, OCUL, AGIO, and DNLI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/22/2025	TYRA Tyra Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
8/18/2025	DNLI Denali Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$33.00 ➝ $30.00
8/6/2025	OCUL Ocular Therapeutix	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$22.00 ➝ $20.00
8/5/2025	OCUL Ocular Therapeutix	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$14.00 ➝ $15.00
7/28/2025	AGIO Agios Pharmaceuticals	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$71.00 ➝ $65.00
7/28/2025	DNLI Denali Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/22/2025	AGIO Agios Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$52.00 ➝ $51.00
7/1/2025	TYRA Tyra Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
5/29/2025	OCUL Ocular Therapeutix	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00

(Data available from 8/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AGIO Agios Pharmaceuticals	$36.50M	61.22	N/A	N/A	$23.57 per share	1.63
DNLI Denali Therapeutics	$330.53M	6.88	N/A	N/A	$7.02 per share	2.22
OCUL Ocular Therapeutix	$63.72M	33.64	N/A	N/A	$1.76 per share	7.00
TYRA Tyra Biosciences	N/A	N/A	N/A	N/A	$5.67 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AGIO Agios Pharmaceuticals	$673.72M	$11.00	3.50	N/A	N/A	1,590.42%	-3.49%	-3.23%	10/30/2025 (Estimated)
DNLI Denali Therapeutics	-$422.77M	-$2.80	N/A	N/A	N/A	N/A	-40.79%	-36.39%	11/5/2025 (Estimated)
OCUL Ocular Therapeutix	-$193.51M	-$1.28	N/A	N/A	N/A	-382.51%	-71.92%	-49.36%	11/13/2025 (Estimated)
TYRA Tyra Biosciences	-$86.48M	-$1.78	N/A	N/A	N/A	N/A	-31.22%	-29.49%	11/6/2025 (Estimated)

Latest TYRA, OCUL, AGIO, and DNLI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	TYRA Tyra Biosciences	-$0.53	-$0.47	+$0.06	-$0.47	N/A	N/A
8/11/2025	Q2 2025	DNLI Denali Therapeutics	-$0.74	-$0.72	+$0.02	-$0.72	$5.64 million	N/A
8/5/2025	Q2 2025	OCUL Ocular Therapeutix	-$0.35	-$0.39	-$0.04	-$0.39	$13.12 million	$13.46 million
7/31/2025	Q2 2025	AGIO Agios Pharmaceuticals	-$1.74	-$1.93	-$0.19	-$1.93	$9.46 million	$12.50 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AGIO Agios Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
DNLI Denali Therapeutics	N/A	N/A	N/A	N/A	N/A
OCUL Ocular Therapeutix	N/A	N/A	N/A	N/A	N/A
TYRA Tyra Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AGIO Agios Pharmaceuticals	N/A	14.48	14.04
DNLI Denali Therapeutics	0.01	10.27	10.27
OCUL Ocular Therapeutix	0.23	10.10	10.02
TYRA Tyra Biosciences	N/A	21.94	21.94

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AGIO Agios Pharmaceuticals	N/A
DNLI Denali Therapeutics	92.92%
OCUL Ocular Therapeutix	59.21%
TYRA Tyra Biosciences	84.14%

Insider Ownership

Company	Insider Ownership
AGIO Agios Pharmaceuticals	4.93%
DNLI Denali Therapeutics	12.50%
OCUL Ocular Therapeutix	2.30%
TYRA Tyra Biosciences	15.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AGIO Agios Pharmaceuticals	390	58.10 million	55.24 million	Optionable
DNLI Denali Therapeutics	430	146.21 million	127.94 million	Optionable
OCUL Ocular Therapeutix	230	173.99 million	169.99 million	Optionable
TYRA Tyra Biosciences	20	53.30 million	45.20 million	Optionable

TYRA, OCUL, AGIO, and DNLI Headlines

Recent News About These Companies

Tyra Biosciences' (TYRA) "Buy" Rating Reaffirmed at HC Wainwright

August 25 at 2:53 AM | americanbankingnews.com

Tyra Biosciences (NASDAQ:TYRA) Earns Buy Rating from HC Wainwright

August 24 at 8:19 AM | marketbeat.com

Brokerages Set Tyra Biosciences, Inc. (NASDAQ:TYRA) PT at $30.83

August 23 at 2:47 AM | americanbankingnews.com

Tyra Biosciences initiates paediatric study for achondroplasia treatment

August 22, 2025 | finance.yahoo.com

Tyra Biosciences Announces First Child Dosed in BEACH301, its Phase 2 Study for Dabogratinib (TYRA-300) in Pediatric Achondroplasia

August 21, 2025 | prnewswire.com

Tyra Biosciences, Inc. (NASDAQ:TYRA) Receives Consensus Rating of "Buy" from Analysts

August 21, 2025 | marketbeat.com

Tyra Biosciences Announces Participation at Upcoming Investor Events

August 20, 2025 | prnewswire.com

DelveInsight Business Research, LLP: FGFR Inhibitors Market Set to Surge by 2034 as Targeted Cancer Therapies Transform Treatment Paradigms | DelveInsight

August 20, 2025 | finanznachrichten.de

FGFR Inhibitors Market Set to Surge by 2034 as Targeted Cancer Therapies Transform Treatment Paradigms | DelveInsight

August 19, 2025 | finance.yahoo.com

Wall Street Analysts See a 178.82% Upside in Tyra Biosciences (TYRA): Can the Stock Really Move This High?

August 19, 2025 | zacks.com

Tyra Biosciences (NASDAQ:TYRA) Shares Gap Up - Here's What Happened

August 17, 2025 | marketbeat.com

Tyra Biosciences (NASDAQ:TYRA) Shares Gap Up After Strong Earnings

August 17, 2025 | americanbankingnews.com

Tyra Biosciences (NASDAQ:TYRA) Releases Earnings Results, Beats Estimates By $0.06 EPS

August 16, 2025 | marketbeat.com

Tyra Biosciences reports Q2 EPS (47c), consensus (51c)

August 14, 2025 | msn.com

Tyra Biosciences Narrows Loss in Q2

August 14, 2025 | aol.comA

Tyra Biosciences Reports Second Quarter 2025 Financial Results and Highlights

August 14, 2025 | prnewswire.com

Urothelial Carcinoma Market Set to Expand During the Forecast Period (2025-2034) Amid Rising Incidence and Evolving Therapeutic Landscape | DelveInsight

August 7, 2025 | uk.finance.yahoo.com

Tyra Biosciences, Inc. (NASDAQ:TYRA) Sees Significant Growth in Short Interest

August 2, 2025 | marketbeat.com

Tyra Biosciences (TYRA) to Release Quarterly Earnings on Wednesday

July 31, 2025 | marketbeat.com

Tyra Biosciences, Inc. (NASDAQ:TYRA) Given Consensus Recommendation of "Buy" by Brokerages

July 26, 2025 | marketbeat.com

Tyra Biosciences Announces Fireside Chat on Achondroplasia and Growth Disorders at UBS Biotech Management Live Call Series

July 21, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TYRA, OCUL, AGIO, and DNLI Company Descriptions

Agios Pharmaceuticals NASDAQ:AGIO

$38.46 +1.20 (+3.22%)

Closing price 04:00 PM Eastern

Extended Trading

$38.50 +0.04 (+0.09%)

As of 06:04 PM Eastern

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Denali Therapeutics NASDAQ:DNLI

$15.55 -0.02 (-0.13%)

Closing price 04:00 PM Eastern

Extended Trading

$15.64 +0.09 (+0.61%)

As of 06:24 PM Eastern

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Ocular Therapeutix NASDAQ:OCUL

$12.32 +0.45 (+3.79%)

Closing price 04:00 PM Eastern

Extended Trading

$12.22 -0.11 (-0.85%)

As of 07:00 PM Eastern

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

Tyra Biosciences NASDAQ:TYRA

$12.64 +0.64 (+5.33%)

Closing price 04:00 PM Eastern

Extended Trading

$12.90 +0.26 (+2.06%)

As of 06:12 PM Eastern

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time